Brynn Marks, MD, MSHPEd, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss a new framework defining fully closed loop insulin delivery.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.

Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, discuss where topical PDE4 inhibitors fit in atopic dermatitis and how to measure skin and itch response.

Shannon C. Trotter, DO, and Mona Shahriari, MD, discuss burnout, people-pleasing, public speaking, and the real life behind physicians’ polished personas.

Retatrutide lowered A1C 2.2% vs 1.8% and cut weight 19.5%-20.9% vs 9.4% with semaglutide 2 mg at 80 weeks in adults with type 2 diabetes.

Vanda’s oral NK-1 receptor antagonist cut any vomiting by 27% vs placebo after a single 1 mg semaglutide dose, and the company plans an sNDA submission.

Alia Galadari, MD, discusses subtle erythema, commonly missed diagnoses, and research gaps to help clinicians recalibrate their approach to skin of color.

Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.